As filed with the Securities and Exchange Commission on March 2, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM F-3
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
Stratasys
Ltd.
(Exact name of registrant as specified in its charter)
Israel |
Not Applicable | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
c/o Stratasys, Inc. | 1 Holtzman Street, Science Park | |
7665 Commerce Way | P.O. Box 2496 | |
Eden Prairie, Minnesota 55344 | Rehovot, Israel 76124 | |
(952) 937-3000 | +972-74-745-4400 | |
(Address and telephone number of registrant's principal executive offices) |
Richard
Garrity
c/o Stratasys, Inc.
7665 Commerce Way
Eden Prairie, Minnesota 55344
(952) 937-3000
(Name, address, and telephone number of agent for service)
Copies to:
J. David Chertok, Adv. | Marc Recht, Esq. |
Jonathan M. Nathan, Adv. | Jaime L. Chase, Esq. |
Meitar | Law Offices | Eric Blanchard, Esq. |
16 Abba Hillel Silver Rd. | Cooley LLP |
Ramat Gan 52506, Israel | 500 Boylston Street, 14th Floor |
Tel: +972-3-610-3100 | Boston, Massachusetts 02116-3736 |
Tel: (617) 937-2316 |
Approximate date of commencement of proposed sale to the public: From
time to time after the effective date of this Registration Statement. If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box. ☐ If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box. ☒ If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. ☐ If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If
this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒ If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ☐ Indicate by check mark whether the Registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933. If an emerging growth company that prepares its financial
statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of
the Securities Act. ☐ † The term “new or revised financial
accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards
Codification after April 5, 2012. CALCULATION OF REGISTRATION FEE
(1) An indeterminate aggregate offering price and number or
amount of securities of each identified class is being registered as may from time to time be offered and sold at indeterminate
prices in one or more offerings. Separate consideration may or may not be received for securities that are issuable on exercise,
conversion or exchange of other securities. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the
“Securities Act”), the securities being registered hereunder include such indeterminate number of securities
as may be issuable with respect to the securities being registered hereunder as a result of stock splits, stock dividends or similar
transactions. (2) In accordance with Rules 456(b) and 457(r) under the Securities
Act, the registrant is deferring payment of the entirety of the registration fee in respect of the offering(s) under this registration
statement. (3) Also includes such indeterminate number of ordinary shares
of the registrant as may be issued upon exercise, conversion or exchange of these other securities. Separate consideration may
or may not be received for securities that are issuable upon exercise, conversion or exchange of other securities. (4) There are being registered hereby such indeterminate number
of warrants as may be issued at indeterminate prices. Such warrants may be issued together with any of the other securities registered
hereby. Warrants may be exercised to purchase any of the other securities registered hereby. PROSPECTUS STRATASYS LTD. ORDINARY SHARES DEBT SECURITIES We may from
time to time offer to sell our ordinary shares, par value 0.01 New Israeli Shekels per share, warrants, debt securities, either
separately or in combination, in one or more offerings, at prices and on terms described in one or more supplements to this prospectus.
In addition, this prospectus may be used to offer ordinary shares for the account of persons other than us. Each time
we or any selling security holder sell securities, we will provide a supplement to this prospectus that contains specific information
about the offering and the terms of the securities. The supplement may also add, update or change information contained in this
prospectus. We may also authorize one or more free writing prospectuses to be provided in connection with a specific offering.
You should read this prospectus, any prospectus supplement and any free writing prospectus before you invest in any of our securities. We or any selling security holder may sell
the securities independently or together with any other securities registered hereunder to or through one or more underwriters,
dealers and agents, or directly to purchasers, or through a combination of these methods, on a continuous or delayed basis. See
“Plan of Distribution.” If any underwriters, dealers or agents are involved in the sale of any of the securities, their
names, any applicable purchase price, fee, commission or discount arrangements between or among them, will be set forth, or will
be calculable from the information set forth, in the applicable prospectus supplement. Our ordinary
shares are traded on the Nasdaq Global Select Market under the symbol “SSYS.” You should read both this prospectus,
any supplement to this prospectus and the additional information described under the heading “Incorporation of Certain Documents
by Reference,” before you decide to invest in our securities. Investing in our securities involves
a high degree of risk. See “Risk Factors” beginning on page 3 of this prospectus, in the documents incorporated
by reference herein or in any applicable supplement to this prospectus to read about factors you should consider before purchasing
our securities. Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
on completeness or the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus is March 1,
2021 TABLE OF CONTENTS i This prospectus
is part of an “automatic shelf” registration statement on Form F-3 that we filed with the U.S. Securities and Exchange
Commission, or the Commission, as a “well-known seasoned issuer” as defined in Rule 405 under the Securities Act of
1933, as amended, or the Securities Act, using a “shelf” registration process. Under this process, we may offer and
sell from time to time, in one or more offerings, the securities described in this prospectus, and certain shareholders may offer
and sell from time to time, in one or more offerings, the ordinary shares described in this prospectus. We sometimes refer
to our ordinary shares as the “shares” throughout this prospectus. When we or
a selling shareholder sell securities, to the extent legally required, we will provide you with a prospectus supplement that describes
the specific amounts, prices and terms of such offering. Such a prospectus supplement may also add, update or change information
contained in this prospectus. You should read carefully both this prospectus and any prospectus supplement together with additional
information described below under “Where You Can Find More Information and Incorporation of Certain Information by Reference.” This prospectus
does not contain all of the information provided in the registration statement of which it is a part that we filed with the Commission.
For further information about us or our ordinary shares, you should refer to that registration statement, which you can obtain
from the Commission as described below under “Where You Can Find More Information and Incorporation of Certain Information
by Reference.” We are responsible
for the information contained in or incorporated by reference in this prospectus and any applicable prospectus supplement and any
free writing prospectus that we prepare or authorize. We have not authorized anyone to provide you with different information,
and we take no responsibility for any other information that others may give you. This prospectus is not an offer to sell these
securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
You should not assume that the information contained in this prospectus and any prospectus supplement is accurate on any date subsequent
to the date set forth on the front of the document or that any information that we have incorporated by reference is correct on
any date subsequent to the date of the document incorporated by reference. Our business, financial condition, results of operations
and prospects may have changed since those dates. We or any
selling shareholders may sell our ordinary shares to underwriters (or, in the case of an offering by us, other securities referred
to in this prospectus and any applicable prospectus supplement) who will sell the shares or other securities to the public at a
fixed offering price or at varying prices determined at the time of sale. In that case, a prospectus supplement will contain the
names of the underwriters, dealers or agents, if any, together with the terms of the offering, and the compensation of those underwriters,
dealers or agents. Any underwriters, dealers or agents participating in the offering may be deemed “underwriters” within
the meaning of the Securities Act. Unless otherwise
mentioned or unless the context requires otherwise, all references in this prospectus to: “Stratasys,”
the “Company,” the “Registrant,” “us,” “we,” “our” and “our company”
are to Stratasys Ltd., an Israeli company, and its consolidated subsidiaries. “Our
shares,” “ordinary shares” and similar expressions refer to our Ordinary Shares, par value 0.01 New Israeli Shekels,
or NIS, per share. “Dollars,”
“US dollars” or “$” are to United States Dollars. About Stratasys Ltd. We are a
global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. Specifically, we
are focused on polymers and technologies that address fast-growing manufacturing solutions, which we view as the biggest potential
growth opportunity in the 3D printing industry. Leveraging distinct competitive advantages that include a broad set of best-in-class
3D printing platforms, software, materials and technology partner ecosystems, innovative leadership, and a global GTM infrastructure,
we are positioned to expand further in a significant and growing global marketplace. Our approximately 1,600 granted and pending
additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for
a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, and
education. Our products and comprehensive solutions improve product quality, development time, cost, and time-to-market. Our additive
manufacturing ecosystem of solutions and expertise includes materials, software, expert services, and on-demand parts production.
By the end of 2020, we estimate that we derived over 25% of our revenues from manufacturing solutions. With the recent acquisition of
Origin Inc., or Origin, a provider of photopolymer solutions for production-oriented applications, which closed on
December 31, 2020, we expanded our leadership through innovation in the fast-growing mass production parts segment with a
next-generation photopolymer platform. Origin’s pioneering approach to additive manufacturing of end-use parts will
enable us to serve a large market with manufacturing-grade 3D printers, utilizing Programmable PhotoPolymerization
(P3). This technology precisely controls light, heat, and force, among other variables, to produce parts with
exceptional accuracy and consistency and enables a broad range of chemistry which turns into unique production grade
properties. Our legal and commercial
name is Stratasys Ltd., and we are the product of the 2012 merger of two leading additive manufacturing companies, Stratasys,
Inc. and Objet Ltd. Stratasys, Inc. was incorporated in Delaware in 1989, and Objet Ltd. was incorporated in Israel in 1998.
As part of that merger transaction, the ordinary shares of Stratasys Ltd. were listed on the Nasdaq Global Select Market
under the trading symbol “SSYS.” We have acquired a number of companies since that time, including: Cooperation
Technology Corporation, or MakerBot, a leader in desktop 3D printing, which owned and operated Thingiverse.com, a website
dedicated to the sharing of user-created digital design files; and Solid Concepts and Harvest Technologies, two leading
providers of additive manufacturing services. Following those last two acquisitions, we introduced our branded Stratasys
Direct Manufacturing, or SDM, service, which significantly broadened and increased our production and offering of AM parts,
which are used by our customers as prototypes, benchmarks and end-use parts. In December 2020, we acquired 3D
printing start-up, Origin Inc., or Origin, and its proprietary P3 Programmable PhotoPolymerization technology,
which we expect to be an important growth engine for our company. The acquisition was aimed at fortifying our leadership in polymers
and production applications of 3D printing in industries such as dental, medical, tooling, and select industrial, defense, and
consumer goods markets. We have dual headquarters. Our registered
office and one of our two principal places of business is located at 1 Holtzman Street, Science Park, P.O. Box 2496, Rehovot 76124,
Israel, and our telephone number at that office is (+972)-74-745-4314. Our other principal place of business is located at 7665
Commerce Way, Eden Prairie, Minnesota, and our telephone number there is (952) 937-3000. Our agent in the United States is Richard
Garrity, President of our Delaware subsidiary, Stratasys, Inc., whose address is c/o Stratasys, Inc. at the address of our Eden
Prairie, Minnesota headquarters. Our website address is www.stratasys.com. The information contained on that website (or on our
other websites, including www.objet.com) is not a part of this prospectus. As an Israeli company, we operate under the provisions
of the Israeli Companies Law, 5759-1999, or the Companies Law. An investment
in our securities involves a high degree of risk. You should carefully consider the risks described in the sections entitled “Risk
Factors” in any prospectus supplement and those set forth in documents incorporated by reference into this prospectus and
any applicable prospectus supplement, including in our most recent Annual Report on Form 20-F filed with the Commission, and in
our quarterly updates to those risk factors contained in the Reports of Foreign Private Issuer on Form 6-K regarding our financial
condition and results of operations that we furnish to the Commission on a quarterly basis, as well as other information in this
prospectus and any prospectus supplement, before purchasing any of our securities. Each of the risks described in these sections
and documents could materially and adversely affect our business, financial condition, results of operations and prospects, and
could result in a loss of your investment. Additional risks and uncertainties known or not known to us or that we deem immaterial
may also impair our business, financial condition, results of operations and prospects. NOTE REGARDING FORWARD-LOOKING STATEMENTS This
prospectus contains, and any accompanying prospectus supplement will contain, forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, and the Private Securities Litigation Reform Act of 1995. Also, documents that we incorporate by reference into this
prospectus, including documents that we subsequently file with the Commission, will contain forward-looking statements. Forward-looking
statements are those that predict or describe future events or trends and that do not relate solely to historical matters. You
can generally identify forward-looking statements as statements containing the words “may,” “will,” “could,”
“should,” “expect,” “anticipate,” “intend,” “estimate,” “believe,”
“project,” “plan,” “assume” or other similar expressions, or negatives of those expressions,
although not all forward-looking statements contain these identifying words. All statements contained or incorporated by reference
into this prospectus and any prospectus supplement regarding our future strategy, future operations, projected financial position,
proposed products, estimated future revenues, projected costs, future prospects, the future of our industry and results that might
be obtained by pursuing management’s current plans and objectives are forward-looking statements. You
should not place undue reliance on our forward-looking statements because the matters they describe are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Our forward-looking statements are based on the information currently
available to us and speak only as of the date on the cover of this prospectus, the date of any prospectus supplement, or, in the
case of forward-looking statements incorporated by reference, the date of the filing that includes the statement. Over time, our
actual results, performance or achievements may differ from those expressed or implied by our forward-looking statements, and such
difference might be significant and materially adverse to our security holders. Except as may be required by applicable law, we
undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events
or otherwise. We
have identified some of the important factors that could cause future events to differ from our current expectations and they may
be described in supplements to this prospectus (if any) under the caption “Risk Factors,” as well as in our most recent
Annual Report on Form 20-F, including without limitation under the captions “Risk Factors” and “Operating and
Financial Review and Prospects,” and in other documents that we may furnish to, or file with, the Commission, all of which
you should review carefully. Please consider our forward-looking statements in light of those risks as you read this prospectus
and any prospectus supplement. OFFER STATISTICS AND EXPECTED TIMETABLE We
will include in an applicable prospectus supplement or in other offering materials the statistics related to any primary offering
by us of our securities, or secondary offering by selling shareholders of ordinary shares, under the registration statement of
which this prospectus forms a part, and the expected timetable for any such offering. Any prospectus supplement or any other offering
materials may also add, update or change information contained in this prospectus. You should carefully read this prospectus, any
prospectus supplement and any other offering materials before you invest in any securities in any such offering. REASONS FOR THE OFFER AND USE OF PROCEEDS Unless
otherwise stated in a prospectus supplement accompanying this prospectus, we are conducting the primary offering hereunder for
general capital raising purposes, and will use the net proceeds from the sale of any securities that we may offer hereunder for
general corporate purposes. Such general corporate purposes may include, but are not limited to, financing possible acquisitions,
working capital, capital expenditures and redeeming outstanding securities. The prospectus supplement relating to an offering will
contain a more detailed description of the reasons for the offering and use of proceeds of any specific offering of securities
(if more specific than what is described in this paragraph). Ordinary
shares may be offered by selling shareholders under a supplement to this prospectus. We will not receive any of the proceeds from
the sale or other disposition of our ordinary shares by the selling shareholders in any offering by them. CAPITALIZATION AND INDEBTEDNESS Each prospectus
supplement will include information on our capitalization and indebtedness. DESCRIPTION OF ORDINARY SHARES
Our authorized share capital consists of (and consisted of, as of December 31, 2020) 180 million ordinary shares, par value NIS
0.01 per share. As of December 31, 2020, we had 56,617,225 ordinary shares outstanding, compared to 54,440,534 ordinary shares
outstanding as of December 31, 2019. The large majority of the additional ordinary shares issued during the 2020 year consisted
of the 1,488,258 ordinary shares that we issued to, or for the benefit of, the stockholders of Origin (including escrow
shares) upon the closing of our acquisition of Origin on December 31, 2020. The remaining ordinary shares issued during 2020 were
issued pursuant to, or upon exercise of, equity awards to directors, officers and/or other employees. As of February 16, 2021,
56,655,816 ordinary shares were issued and outstanding. We
may from time to time, by approval of a majority of our shareholders, increase our authorized share capital. Our fully paid ordinary
shares are issued in registered form and, subject to applicable securities laws, are freely transferable under our amended and
restated articles of association, as further amended (to which we refer herein as our amended articles). Under the Israeli Companies
Law, 5759-1999, or the Companies Law, we are required to maintain a major shareholder register listing for shareholders holding
5% or more of our outstanding ordinary shares. Our
amended articles and the laws of the State of Israel do not restrict the ownership or voting of ordinary shares by non-residents
of Israel, except with respect to individuals and entities that are residents of countries in a state of war with Israel, and except
with respect to entities which are controlled by residents of countries in a state of war with Israel. Listing, Register Number and Purpose Our
ordinary shares are listed and traded on the Nasdaq Global Select Market under the trading symbol “SSYS.” Our
registration number at the Israeli Registrar of Companies is 51-260769-8. Our purpose under our memorandum of association
and amended articles is to conduct all types of business as are permitted by law. Dividend and Liquidation Rights Subject
to any preferential, deferred or other rights or restrictions attached to any special class of shares with regard to dividends, holders
of our ordinary shares are entitled to their proportionate share of any cash dividend, share dividend or dividend in kind declared
with respect to our ordinary shares. Under the Companies Law and our amended articles, we may declare dividends only out of our
“profits,” as such term is defined in the Companies Law, and provided that the distribution does not create a reasonable
concern that the Company will be unable to meet its existing and anticipated obligations as they become due, or the “solvency
test.” Notwithstanding the foregoing, dividends may be paid even if we do not have “profits,” with the approval
of a court, provided that we meet the aforesaid solvency test. “Profits,” for purposes of the Companies Law, means
the greater of retained earnings or earnings accumulated during the preceding two years, after deduction of previous distributions
that were not already deducted from the surpluses, as evidenced by the most recent audited or reviewed financial statements of
the company prepared no more than six months prior to the date of distribution. Under
the Companies Law, the declaration of a dividend does not require the approval of the shareholders of a company unless the company’s
articles of association provide otherwise. Our amended articles provide that our board of directors may declare and distribute
dividends without the approval of the shareholders Our amended articles provide and that our
board of directors is entitled to invest any dividend which has not been claimed for a period of one (1) year after
having been declared, or to make use thereof in any other way for the benefit of the Company until such time as it is claimed.
We are not obligated to pay interest or linkage on an unclaimed dividend. In
the event of liquidation, holders of our ordinary shares will have the right to share ratably in any assets remaining after payment
of liabilities, in proportion to the paid-up par value of their respective holdings. These rights may be affected by the grant
of preferential liquidation or dividend rights to the holders of a class of shares that may be authorized in the future. Shareholder Meetings Holders
of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders. This right may
be changed if shares with special voting rights are authorized in the future. Under
the Companies Law, an annual general meeting of our shareholders should be held once every calendar year, but no later than 15
months from the date of the previous annual general meeting. All
meetings other than the annual general meeting of shareholders are referred to as extraordinary general meetings. Our board of
directors may call extraordinary general meetings whenever it sees fit, at such time and place, within or outside of Israel, as
it may determine. In addition, the Companies Law and our amended articles provide that our board of directors is required to convene
an extraordinary general meeting upon the written request of (i) any two of our directors or one-quarter of our board of directors
or (ii) one or more shareholders holding, in the aggregate, either (a) 5% of our outstanding issued shares and 1% of our outstanding
voting power or (b) 5% of our outstanding voting power. The Chairman of the Board of Directors or any other person appointed by
the Board of Directors for this purpose, presides at each of our general meetings. Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders that are entitled to participate
and vote at general meetings are the shareholders of record on a date decided by our board of directors, which may be between four
and 40 days prior to the date of the meeting. Furthermore, the Companies Law and the amended articles generally require that resolutions
regarding the following matters will be passed at a general meeting of our shareholders: The
Companies Law and the amended articles require that a notice of any annual general meeting or extraordinary general meeting be
provided to shareholders at least 21 days prior to the meeting, and if the agenda of the meeting includes the appointment or removal
of directors, the approval of transactions with office holders or interested or related parties, including appointing of a chief
executive officer of a company to a concurrent office as the chairman of the board of directors, or an approval of a merger, notice
must be provided at least 35 days prior to the meeting. Under
the Companies Law and the amended articles, shareholders are not permitted to take action via written consent in lieu of a meeting. Voting Rights Quorum requirements Pursuant
to our amended articles, holders of ordinary shares have one vote for each share held on all matters submitted to a vote before
the shareholders at a general meeting. The quorum required for a general meeting consists of at least two shareholders present
in person, by proxy or written ballot who hold or represent between them at least 25% of the total outstanding voting rights in
the Company. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same
time and place or to a later time and date if so specified in the notice of the meeting. At the reconvened meeting, any two or
more shareholders present in person or by proxy constitute a lawful quorum. Vote requirements Our amended
articles provide that all resolutions of our shareholders require the approval of a majority of the voting power present and voting
at a general meeting, in person or by proxy, unless otherwise required by the Companies Law or by the amended articles. Under the
Companies Law, subject to certain exceptions, each of (i) the approval of an extraordinary transaction with a controlling shareholder
or in which a controlling shareholder has a personal interest, (ii) the terms of employment or other engagement of the controlling
shareholder of the company or such controlling shareholder’s relative (even if not constituting an extraordinary transaction) and
(iii) the terms of employment of the chief executive officer, require, in addition to approval by the audit committee (or, in the
case of a compensatory arrangement, the compensation committee) and the board of directors, approval by a simple majority of the
shareholders, provided such majority fulfills one of the following requirements: Under the Companies Law, an extraordinary
transaction is a transaction: not in the ordinary course of business, not on market terms, or that is likely to have a material
impact on the company’s profitability, assets or liabilities. Under our amended articles, if our share
capital is divided into classes, the alteration of the rights, privileges, preferences or obligations of any class of share capital
will require approval by a majority of the voting power present and voting, in person or by proxy, at a class meeting of the class
so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class). Shareholder Duties The Companies Law provides that a shareholder,
in exercising his or her rights and performing his or her obligations toward the company and its other shareholders, must act in
good faith and in a customary manner, and avoid abusing his or her power, among other things, when voting at general meetings on
matters such as changes to the articles of association, increasing the company’s registered capital, mergers and approval
of related party transactions. In addition, specified shareholders have a duty of fairness toward the company. These shareholders
include any controlling shareholder, any shareholder who knows that it possesses the power to determine the outcome of a shareholder
vote and any shareholder who, pursuant to the provisions of the company’s articles of association, has the power to appoint
or prevent the appointment of an office holder or any other power with respect to the company. The Companies Law does not define
the substance of this duty of fairness. However, a shareholder’s breach of the duty of fairness is subject to laws regarding
breaches of contracts and takes into account the status of such shareholder with respect to the company. Access to Corporate Records Under the Companies Law and our amended
articles, shareholders are provided access to the following corporate records: minutes of our general meetings; our shareholders
register and principal shareholders register, our amended articles and financial statements; and any document that we are required
by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may
request to be provided with any document related to an action or transaction requiring shareholder approval under the related party
transaction provisions of the Companies Law. We may deny this request if we believe it has not been submitted in good faith or
if such denial is necessary to protect our interest or protect a trade secret or patent. Modification of Class Rights The rights attached to any class of shares,
such as voting, liquidation and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the
shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of
shares, as set forth in our amended articles. Transfer Agent and Registrar Our transfer agent and registrar in the
United States is Continental Stock Transfer & Trust Company. Registration Rights None of our shareholders currently has
the right to request that we register the sale of our ordinary shares for them, other than shareholders that have been issued,
or may in the future be issued, ordinary shares by us pursuant to our acquisition of Origin, which was consummated on December
31, 2020, and for which we filed, on January 7, 2020, a registration statement on Form F-3 in order to fulfill our obligation to
register the resale of those shares under the definitive agreement whereby we acquired Origin. Anti-Takeover Provisions Except for provisions in our amended articles
that contain procedural guidelines and disclosure requirements with respect to the submission of shareholder proposals for shareholders
meetings, there are no specific provisions of our memorandum, amended articles or other constituent documents that would have an
effect of delaying, deferring or preventing a change in control of the Company or that would operate only with respect to a merger,
acquisition or corporate restructuring involving us (or any of our subsidiaries). However, as described below, certain provisions
of the Companies Law may have such effects. Full Tender Offer A person wishing
to acquire shares of a public Israeli company and who could as a result hold over 90% of the target company’s issued and
outstanding share capital or voting rights (or a class thereof) is required by the Companies Law to make a tender offer to all
of the target company’s shareholders for the purchase of all of the issued and outstanding shares of the target company (or
the applicable class). If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital
and voting rights of the company or of the applicable class, all of the shares that the acquirer offered to purchase will be transferred
to the acquirer by operation of law (provided that a majority of the offerees that do not have a personal interest in such tender
offer shall have approved it). However, a tender offer will also be accepted if the shareholders who do not accept the offer hold
less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. A shareholder who
had its shares so transferred, regardless of whether such shareholder agreed to the offer, may, at any time within six months
following the completion of the tender offer, petition the court to determine whether the tender offer was for less than fair value
and whether the fair value should be paid as determined by the court. However, an offeror may stipulate in the tender offer document
that a shareholder who accepts the offer waives its appraisal rights. If a tender offer is not accepted in accordance with the
requirements set forth above, the acquirer may not acquire shares of the company that will increase its holdings to more than 90%
of the company’s issued and outstanding share capital or voting rights or 90% of the shares or voting rights of the applicable
class, from shareholders who accepted the tender offer. Special Tender Offer The Companies
Law provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a
result of the acquisition the purchaser could become a holder of 25% or more of the voting rights in the company, unless one of
the exemptions in the Companies Law (as described below) is met. This rule does not apply if there is already another holder of
at least 25% of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public
company must be made by means of a tender offer if as a result of the acquisition the purchaser could become a holder of more than
45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting
rights in the company, unless one of the exemptions in the Companies Law is met. These requirements
do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder
approval as a private placement whose purpose is to give the acquirer at least 25% of the voting rights in the company if there
is no person who holds 25% or more of the voting rights in the company, or as a private placement whose purpose is to give the
acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company, (ii) was
from a shareholder holding 25% or more of the voting rights in the company and resulted in the acquirer becoming a holder of 25%
or more of the voting rights in the company, or (iii) was from a holder of more than 45% of the voting rights in the company
and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A special tender
offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than
5% of the voting power attached to the company’s outstanding shares, regardless of how many shares are tendered by shareholders.
A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company’s outstanding
shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders
objected to the offer. If a special tender
offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such
controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not
enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person
or entity undertook to effect such an offer or merger in the initial special tender offer. Merger The Companies Law
permits merger transactions if approved by each party’s board of directors and, unless certain requirements described under
the Companies Law are met, by a majority vote of each party’s shares, and, in the case of the target company, a majority
vote of each class of its shares, voted on the proposed merger at a shareholders meeting called with at least 35 days’ prior
notice. For purposes of
the shareholder vote, unless a court rules otherwise, the merger requires approval by a majority of the votes of shares represented
at the shareholders’ meeting that are held by parties other than the other party to the merger, or by any person (or group
of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint
25% or more of the directors of the other party to the merger. If, however, the merger involves a merger with a company’s
own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead
subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described
above under “Voting Rights—Vote requirements”). If the transaction
would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion
of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at
least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the
value of the parties to the merger and the consideration offered to the shareholders of the company that have petitioned the court
to approve the merger. Upon the request
of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists
a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of
the parties to the merger, and may further give instructions to secure the rights of creditors. In addition, a merger
may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed
by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved
by the shareholders of each party. Preferred Share Issuance Under the Companies Law, we are allowed
to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain
preferred rights, distributions or other matters and shares having preemptive rights. No preferred shares are currently authorized
under our amended articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class
of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover
or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization
and designation of a class of preferred shares will require an amendment to our amended articles, which requires the prior approval
of the holders of a majority of the voting power present and voting, in person or by proxy, at the applicable general meeting of
our shareholders. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained
at such a meeting will be subject to the requirements set forth in the Companies Law as described above under “—Voting
Rights.” DESCRIPTION OF OTHER SECURITIES We
will set forth in an applicable prospectus supplement a description of any warrants to purchase our ordinary shares or debt securities
that we may offer under this prospectus. The general form of indenture pursuant to which such debt securities may be offered is
set forth as Exhibit 4.4 to the registration statement of which this prospectus is a part. Certain income
tax considerations relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will
be set forth in the applicable prospectus supplement relating to the offering of those securities. If the registration statement of which
this prospectus is a part is used by any selling shareholder for the resale of any ordinary shares registered thereunder, information
about such selling shareholder, its beneficial ownership of our securities and its relationship with us will be set forth in a
post-effective amendment to the registration statement, in a supplement to this prospectus, or in one or more documents incorporated
by reference into this prospectus or the applicable prospectus supplement. We may offer and sell our securities, and any selling shareholders
may offer and sell shares, in offerings hereunder to or through one or more underwriters, dealers and agents, or directly to purchasers,
on a continuous or delayed basis. We will provide the specific plan of distribution for any securities to be offered by us or by
selling shareholders in a supplement to this prospectus. The following table sets forth our expenses
(other than underwriting discounts and commissions) in connection with the offering described in the registration statement of
which this prospectus is a part: * In accordance with Rules 456(b) and 457(r) under the Securities Act, we are deferring payment of the registration fee for securities
offered under this prospectus. **Estimated expenses in respect of offerings hereunder are not
presently known. Once known, such expenses will be disclosed in separate prospectus supplements required to be filed in connection
with any such offerings, or as an exhibit to a filing with the Commission pursuant to the Exchange Act that is incorporated by
reference into this prospectus. The
validity of the ordinary shares offered by this prospectus will be passed upon by Meitar
Law Offices, Ramat-Gan, Israel. Unless otherwise indicated in the applicable prospectus supplement, the validity and
enforceability of the warrants and debt securities offered by this prospectus, and any supplement thereto, will be passed
upon for us by Cooley LLP, Boston, Massachusetts. The financial statements and management’s
assessment of the effectiveness of internal control over financial reporting (which is included in Management’s Annual
Report on Internal Control over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form
20-F for the year ended December 31, 2020 have been so incorporated in reliance on the report of Kesselman &
Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered
public accounting firm, given on the authority of said firm as experts in auditing and accounting. WHERE YOU CAN FIND MORE INFORMATION We
are an Israeli company and are a "foreign private issuer" as defined in Rule 3b-4 under the Exchange Act. As a result,
(1) our proxy solicitations are not subject to the disclosure and procedural requirements of Regulation 14A under the
Exchange Act, and (2) transactions in our equity securities by our officers and directors are exempt from Section 16
of the Exchange Act. In
addition, we are not required to file reports and financial statements with the Commission as frequently or as promptly as U.S.
companies whose securities are registered under the Exchange Act. However, we file with the Commission an Annual Report on Form 20-F
containing financial statements audited by an independent registered public accounting firm. We also furnish Reports of Foreign
Private Issuer on Form 6-K containing unaudited financial information for the first three quarters of each fiscal year and
other material information that we are required to make public in Israel, that we file with, and that is made public by, any stock
exchange on which our shares are traded, or that we distribute, or that is required to be distributed by us, to our shareholders. You
can read and copy any materials we file with the Commission at its website, which you can access at http://www.sec.gov. You may
also access the information that we file electronically with the Commission through our website at http://www.stratasys.com. The
information contained on, or linked from, our website does not form part of this prospectus. This
prospectus is part of a registration statement on Form F-3 filed by us with the Commission under the Securities Act. As permitted
by the rules and regulations of the Commission, this prospectus does not contain all of the information set forth in the registration
statement and the exhibits thereto filed with the Commission. For further information with respect to us and the ordinary shares,
warrants and debt securities that may be offered hereby by us, or the ordinary shares that may be offered by selling shareholders,
you should refer to the complete registration statement on Form F-3, including any prospectus supplement, which may be obtained
from the locations described above. Statements contained in this prospectus or in any prospectus supplement about the contents
of any contract or other document are not necessarily complete. If we have filed any contract or other document as an exhibit to
the registration statement or any other document incorporated by reference into the registration statement, you should read the
exhibit for a more complete understanding of the document or matter involved. Each statement regarding a contract or other document
is qualified in its entirety by reference to the actual document. We incorporate
by reference into this prospectus the documents listed below, and any future Annual Reports on Form 20-F, and all subsequent
Reports of Foreign Private Issuer on Form 6-K (to the extent that any such Form 6-K indicates that it is intended to
by incorporated by reference herein) filed with or furnished to the Commission pursuant to the Exchange Act prior to the termination
of the offering. The documents that we incorporate by reference are: The information that we incorporate by
reference is an important part of this prospectus, and later information that we file with the Commission will automatically be
incorporated into, update and supersede the information contained in this prospectus. Unless expressly incorporated by reference,
nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the Commission.
We shall provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference
into this prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents.
Please direct your written or telephone requests to us at Stratasys Ltd., 1 Holtzman Street, Science Park, P.O. Box 2496,
Rehovot 76124, Israel, Attention: Yonah Lloyd—Chief Communications Officer, Telephone: +972-74-745-4300, email: Yonah.Lloyd@stratasys.com. ENFORCEABILITY OF CIVIL LIABILITIES We are incorporated under
the laws of the State of Israel. Service of process upon us and upon our directors, officers and any Israeli experts named in this
prospectus, substantially all of whom reside outside of the United States, may be difficult to obtain within the United States.
Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside of
the United States, any judgment obtained in the United States against us or any of our directors and officers may not
be collectible within the United States. We have been informed by
our legal counsel in Israel, Meitar Law Offices, that it may be difficult to assert U.S. securities law claims in original actions
instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws because Israel
is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim,
it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content
of applicable U.S. law must be proven as a fact, which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law. We have irrevocably appointed
Stratasys, Inc. as our agent to receive service of process in any action against us in any United States federal or state
court arising out of the offering under this prospectus or any purchase or sale of securities in connection with any such offering.
Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil
matter which, subject to certain exceptions, is non-appealable, including a judgment based upon the civil liability provisions
of the Securities Act or the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided
that, among other things: If a foreign judgment is enforced by an
Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and
transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency
is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on
the date of the judgment. Current Israeli exchange control regulations also permit a judgment debtor to make payment in foreign
currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked
to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time.
Judgment creditors must bear the risk of unfavorable exchange rates.
PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 8. Indemnification of Directors and Officers Under the Companies Law, a company
may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office
holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach
of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and
restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising
out of a prohibited dividend or distribution to shareholders. Under the Companies Law, a company
may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as
an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of
association include a provision authorizing such indemnification: Under the Companies Law, a company
may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder, if
and to the extent provided in the company’s articles of association: Under the Companies Law, a company
may not indemnify, exculpate or insure an office holder against any of the following: Under the Companies Law, exculpation,
indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board
of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. Our articles permit us to exculpate,
indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law. We have obtained
directors’ and officers’ liability insurance for the benefit of our office holders and intend to continue to maintain
such coverage and pay all premiums thereunder to the fullest extent permitted by the Companies Law. In addition, we have entered
into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us
as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our
articles and Israeli law, including with respect to liabilities resulting from a public offering of our shares, to the extent that
these liabilities are not covered by insurance. Each of
the foregoing indemnification obligations is limited both in terms of amount and coverage. In the opinion of the Commission, however,
indemnification of directors and office holders for liabilities arising under the Securities Act is against public policy and therefore
unenforceable. Item 9. Exhibits Item 10. Undertakings (a) The undersigned registrant hereby
undertakes: (1) to file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required
by section 10(a)(3) of the Securities Act of 1933 (the “Securities Act”); (ii) To reflect in the prospectus any
facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation
of Registration Fee” table in the effective registration statement; (iii) To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such
information in the registration statement; provided, however, that paragraphs (a)(1)(i),
(a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13
or section 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) that are incorporated by reference into
the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration
statement. (2) That, for the purpose of determining
any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. (3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. (4) To file a post-effective amendment
to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed
offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the
Securities Act need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment,
financial statements required pursuant to this paragraph (4) and other information necessary to ensure that all other information
in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, a post-effective
amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act
or Item 8. A. of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished
to the Commission by the registrant pursuant to Section 13 or Section 15 (d) of the Exchange Act that are incorporated by reference
into the registration statement. (5) That, for the purpose of determining
liability under the Securities Act to any purchaser: (i) (a) Each prospectus filed by the registrant
pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed
part of and included in the registration statement; and (b) Each prospectus required to be filed
pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the
Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form
of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described
in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of
the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately prior to such effective date. (6) That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser
and will be considered to offer or sell such securities to such purchaser: (i) Any preliminary prospectus or prospectus
of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) Any free writing prospectus relating
to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) The portion of any other free writing
prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and (iv) Any other communication that is an
offer in the offering made by the undersigned registrant to the purchaser. (b) The undersigned registrant hereby
undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s
annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing
of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated
by reference into the registration statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. (c) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of
1933 and will be governed by the final adjudication of such issue. (d) To file an application for the purpose
of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act of 1939 in
accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Trust Indenture Act of 1939. SIGNATURES Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form F-3 and has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunder duly authorized, in the city of Rehovot, Israel, on March 2, 2021. KNOW ALL PERSONS BY THESE PRESENTS that
the undersigned officers and directors of Stratasys Ltd., an Israeli company, do hereby constitute and appoint Yoav Zeif, Chief
Executive Officer, and Lilach Payorski, Chief Financial Officer, and each of them, their lawful attorneys-in-fact and agents with
full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents,
and any one of them, determine may be necessary or advisable or required to enable said company to comply with the Securities Act
of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with
this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the
power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration
Statement, to any and all post-effective amendments and supplements to this Registration Statement, and to any and all instruments
or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each
of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be
done by virtue hereof. This Power of Attorney may be signed in several counterparts. IN WITNESS WHEREOF, each of the undersigned
has executed this Power of Attorney as of the date indicated. Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the
dates indicated. AUTHORIZED REPRESENTATIVE IN Stratasys, Inc.
Emerging growth company ☐
Proposed
Proposed
maximum
maximum
Amount of
Title of each class of
Amount to be
aggregate price
aggregate offering
registration
securities to be
registered
registered
per
unit
price
fee
Ordinary Shares, par value 0.01
(1)
(1)
(1)
(2)
New Israeli Shekels
per share (“Ordinary Shares”)
Warrants(3)(4)
(1)
(1)
(1)
(2)
Debt Securities(3)
(1)
(1)
(1)
(2)
WARRANTS 1 2 3 4
● amendments to the amended articles;
● appointment or termination of our auditors;
● appointment of directors and appointment and dismissal of external
directors;
● approval of certain acts and transactions involving related parties,
as defined by the Companies Law or pursuant to our amended articles, as further described below;
● director compensation;
● increases or reductions of our authorized share capital;
● a merger;
● the exercise of our board of directors’ powers by a general
meeting, if the board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper
management; and
● certain liquidation events. 5
● the majority that voted in favor of the matter includes a majority
of non-controlling shareholders who do not have a personal interest in the matter; or
● the votes of non-controlling shareholders who do not have a personal
interest in the matter and who vote against such matter represent less than two percent (2%) of the voting rights of the company. 6 7 8
SEC registration fee
$
*
Printing, EDGAR and photocopying fees
$
**
Legal fees and expenses
$
**
Accounting fees and expenses
$
**
Miscellaneous expenses
$
**
Total
$
**
9
AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 10
● our Annual Report on Form 20-F for the year ended December 31, 2020,
filed with the Commission on March 1, 2021, which we refer to as the 2020 Annual Report; and
● the description of our ordinary shares set forth under “Item 1. Description of Registrant's
Securities to be Registered” in our Registration Statement on Form 8-A, filed with the Commission on December 3,
2012, as supplemented by Exhibit 2.2 to the 2020 Annual Report, and as may be further updated or amended in any amendment or report
filed for such purpose.
● the judgment is obtained after due process before a court
of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international
law prevailing in Israel;
● the judgment is executory in the state in which it was
given;
● the prevailing law of the foreign state in which the
judgment is rendered allows for the enforcement of judgments of Israeli courts;
● adequate service of process has been effected and the
defendant has had a reasonable opportunity to be heard and to present his or her evidence;
11
● the judgment is not contrary to public policy of Israel,
and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of
Israel;
● the judgment was not obtained by fraud and does not conflict
with any other valid judgment in the same matter between the same parties;
● an action between the same parties in the same matter
was not pending in any Israeli court at the time at which the lawsuit was instituted in the foreign court; and
● the judgment is enforceable according to the laws of
Israel and according to the law of the foreign state in which the relief was granted.
12
● a financial liability incurred by or imposed on him or
her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s award approved by a court.
However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking
must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities
when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as
reasonable under the circumstances, and such undertaking shall detail the above-mentioned foreseen events and amount or criteria;
● reasonable litigation expenses, including attorneys’
fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an
authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such
office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her
as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was
imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection
with a monetary sanction;
● reasonable litigation expenses, including attorneys’
fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its
behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result
of a conviction for an offense that does not require proof of criminal intent; and
● reasonable litigation expenses, including attorneys’
fees, incurred by the office holder in respect of certain administrative proceedings under the Israeli Securities Law.
● a breach of the duty of loyalty to the company, provided
that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
● a breach of duty of care to the company or to a third
party, to the extent such a breach arises out of the negligent conduct of the office holder; and
● a financial liability imposed on the office holder in
favor of a third party.
II-1
● a breach of the duty of loyalty, except for indemnification
and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and
had a reasonable basis to believe that the act would not harm the company;
● a breach of duty of care committed intentionally or recklessly,
excluding a breach arising solely out of the negligent conduct of the office holder;
● an act or omission committed with intent to derive illegal
personal benefit; or
● a fine, civil fine, monetary sanction or forfeit levied
against the office holder.
Exhibit Number
Exhibit
1.1
Form of Underwriting Agreement **
4.1
Amended and Restated Articles of Association of the Registrant (1)
4.2
Memorandum of Association of the Registrant (2)
4.3
Specimen ordinary share certificate of the Registrant (3)
4.4
Form of Debt Indenture*
4.5
Form of Debt Securities**
4.6
Form of Warrant Agreement**
4.7
Form
of Warrant Certificate**
5.1
Opinion of Meitar Law Offices as to the ordinary shares being registered*
5.2
Opinion of Cooley LLP as to the warrants and debt securities being registered*
23.1
Consent of Kesselman & Kesselman, an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited *
23.2
Consent of Meitar Law Offices (included in Exhibit 5.1)*
23.5
Consent of Cooley LLP (included in Exhibit 5.2)*
24
Power of Attorney (included on the signature page of this Registration Statement)*
25
Statement of Eligibility of Trustee under the Debt Indenture***
(1)
Incorporated by reference to Appendix A to the registrant’s proxy statement for its February 3, 2015 extraordinary general meeting of shareholders, attached as Exhibit 99.1 to the Registrant’s Report of Foreign Private Issuer on Form 6-K furnished to the Commission on January 6, 2015.
(2)
Incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form F-4 (Commission File No. 333-182025), filed with the Commission on June 8, 2012.
(3)
Incorporated by reference to Exhibit 4.1 to Amendment No. 3 to the Registrant’s Registration Statement on Form F-4 (Commission File No. 333-182025), filed with the Commission on August 6, 2012.
*
Filed herewith
**
To be filed by amendment or as an exhibit to a filing with the Commission pursuant to the Exchange Act and incorporated herein by reference, if applicable.
***
To be filed separately under electronic form type 305B2, if applicable. II-2 II-3 II-4
STRATASYS LTD.
By:
/s/ Yoav Zeif
Name: Yoav Zeif
Title: Chief Executive Officer
Signature
Title
Date
/s/
Yoav Zeif
Chief Executive Officer
March
2, 2021
Yoav Zeif
(Principal Executive Officer) and Director
/s/
Lilach Payorski
Chief Financial Officer
March
2, 2021
Lilach Payorski
(Principal Financial and Accounting Officer)
/s/
Dov Ofer
Chairman of the Board
March
2, 2021
Dov Ofer
/s/
Zeev Holtzman
Director
March
2, 2021
Zeev Holtzman
/s/
John J. McEleney
Director
March
2, 2021
John J. McEleney
/s/
Ziva Patir
Director
March
2, 2021
Ziva Patir
/s/
David Reis
Director
March
2, 2021
David Reis
/s/ Michael Schoellhorn
Director
March
2, 2021
Michael
Schoellhorn
/s/ Yair Seroussi
Director
March 2, 2021
Yair Seroussi
/s/ Adina Shorr
Director
March 2, 2021
Adina Shorr
THE UNITED STATES:
By:
/s/ Richard Garrity
Name: Richard Garrity
Title: President
Date: March 2, 2021 II-5